诊断学方法模型在顺铂副作用中的应用
Application of Diagnostic Method Model in Side Effects of Cisplatin
DOI: 10.12677/MD.2018.84010, PDF,   
作者: 韩建冬, 王美玲, 格根塔娜, 杜艳青, 梁凤英, 额尔敦：内蒙古医科大学，内蒙古 呼和浩特
关键词: 诊断学；顺铂；副作用；Diagnostics； Cisplatin； Side Effects
摘要: 顺铂是一种经典抗肿瘤药物，用于治疗各种各样的恶性肿瘤。然而，其主要的剂量限制的副作用是肾损伤。为了帮助理解肾损伤发展中涉及的机制，已开发出探究顺铂副作用的啮齿动物模型。鉴于肾损伤的复杂发病机制，其涉及肾脏中的局部作用以及体内相互依赖的全身作用，动物模型在研究急性和慢性肾损伤的潜在机制和潜在治疗策略中是必不可少的。尽管方法学诊断的动物模型具有简单性和广泛适用性，但在使用顺铂各种各样诊断学模型时也需要考虑各种模型的缺陷。本文旨在简要介绍诊断学方法在顺铂副作用中的应用，其中主要以动物模型为主，并且比较各种模型的异同点，以及可能严重影响模型和研究结果的概述因素。
Abstract: Cisplatin is a classic anti-tumor drug used to treat a wide variety of malignancies. However, the main side effect of its dose limitation is kidney damage. To help understand the mechanisms involved in the development of kidney damage, rodent models have been developed to explore the side effects of cisplatin. Given the complex pathogenesis of kidney injury, which involves local effects in the kidney and interdependent systemic effects in vivo, animal models are essential in studying the underlying mechanisms and potential therapeutic strategies for acute and chronic kidney injury. Despite the simplicity and wide applicability of animal models for methodological diagnosis, the deficiencies of various models need to be considered when using various diagnostic models of cisplatin. This article aims to briefly introduce the application of diagnostic methods in the side effects of cisplatin, mainly based on animal models, and compare the similarities and differences of various models, as well as the summary factors that may seriously affect the model and research results.
文章引用：韩建冬, 王美玲, 格根塔娜, 杜艳青, 梁凤英, 额尔敦. 诊断学方法模型在顺铂副作用中的应用[J]. 医学诊断, 2018, 8(4): 63-68. https://doi.org/10.12677/MD.2018.84010

参考文献

[1] Uccelli, A., Moretta, L. and Pistoia, V. (2008) Mesenchymal Stem Cells in Health and Disease. Nature Reviews Immunology, 8, 726-736. [Google Scholar] [CrossRef] [PubMed]
[2] Chawla, L.S., Eggers, P.W., Star, R.A. and Kimmel, P.L. (2014) Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes. The New England Journal of Medicine, 371, 58-66. [Google Scholar] [CrossRef] 
[3] Ozkok, A. and Edelstein, C.L. (2014) Pathophysiology of Cisplatininduced Acute Kidney Injury. BioMed Research International, 2014, Article ID: 967826.
[4] Zhang, J., Goering, P.L., Espandiari, P., et al. (2009) Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-, and Valproic Acid-Treated Rats: Potential Role of iNOS and Nitrotyrosine. Toxicologic Pathology, 37, 629-643. [Google Scholar] [CrossRef] [PubMed]
[5] Cepeda, V., Fuertes, M.A., Castilla, J., Alonso, C., Quevedo, C. and Pérez, J.M. (2007) Biochemical Mechanisms of Cisplatin Cytotoxicity. Anti-Cancer Agents in Medicinal Chemistry, 7, 3-18. [Google Scholar] [CrossRef] [PubMed]
[6] Zhu, S., Pabla, N., Tang, C., He, L. and Dong, Z. (2015) DNA Damage Response in Cisplatin-Induced Nephrotoxicity. Archives of Toxicology, 89, 2197-2205. [Google Scholar] [CrossRef] [PubMed]
[7] Ali, B.H. and Al Moundhri, M.S. (2006) Agents Ameliorating or Augmenting the Nephrotoxicity of Cisplatin and Other Platinum Compounds: A Review of Some Recent Research. Food and Chemical Toxicology, 44, 1173-1183. [Google Scholar] [CrossRef] [PubMed]
[8] Večerić-Haler, Ž., Cerar, A. and Perse, M. (2017) (Mesenchymal) Stem Cell-Based Therapy in Cisplatin-Induced Acute Kidney Injury Animal Model: Risk of Immunogenicity and Tumorigenicity. Stem Cells Interna-tional, 2017, Article ID: 7304643.
[9] Heyman, S.N., Rosen, S. and Rosenberger, C. (2009) Animal Models of Renal Dysfunction: Acute Kidney Injury. Expert Opinion on Drug Discovery, 4, 629-641.
[10] Dobyan, D.C., Levi, J., Jacobs, C., Kosek, J. and Weiner, M.W. (1980) Mechanism of Cis-Platinum Nephrotoxicity: II. Morphologic Observations. The Journal of Pharmacology and Experi-mental Therapeutics, 213, 551-556.
[11] Dobyan, D.C. (1985) Long-Term Consequences of Cis-Platinuminduced Renal Injury: A Structural and Functional Study. Anatomical Record, 212, 239-245. [Google Scholar] [CrossRef] [PubMed]
[12] Sendao, M.C., Francescato, H.D., Antunes, L.M., Costa, R.S. and Bianchi Mde, L. (2006) Comparative Study of Multiple Dosage of Quercetin against Cisplatin-Induced Nephrotoxicity and Oxidative Stress in Rat Kidneys. Pharmacological Reports, 58, 526-532.
[13] Amate, J.Y., Ishida, A., Tsujino, K., et al. (1996) Immunohistochemical Study of Rat Renal Interstitial Fibrosis Induced by Repeated Injection of Cisplatin, with Special Reference to the Kinetics of Macrophages and Myofibroblasts. Toxicologic Pathology, 24, 199-206. [Google Scholar] [CrossRef] [PubMed]
[14] Yamate, J., Sato, K., Ide, M., et al. (2002) Participation of Different Macrophage Populations and Myofibroblastic Cells in Chronically Developed Renal Interstitial Fibrosis after Cisplatin-Induced Renal Injury in Rats. Veterinary Pathology, 39, 322- 333. [Google Scholar] [CrossRef] [PubMed]
[15] Yamate, J., Machida, Y., Ide, M., et al. (2005) Cisplatin-Induced Renal Interstitial Fibrosis in Neonatal Rats, Developing as Solitary Nephron Unit Lesions. Toxicologic Pathology, 33, 207-217. [Google Scholar] [CrossRef] [PubMed]
[16] Palant, C.E., Amdur, R.L. and Chawla, L.S. (2016) The Acute Kidney Injury to Chronic Kidney Disease Transition: A Potential Opportunity to Improve Care in Acute Kidney Injury. Contributions to Nephrology, 187, 55-72.
[17] Palant, C.E., Chawla, L.S., Faselis, C., et al. (2016) High Serum Creatinine Nonlinearity: A Renal Vital Sign? American Journal of Physiology Renal Physiology, 311, F305-F309. [Google Scholar] [CrossRef] [PubMed]
[18] Sharp, C.N. and Siskind, L.J. (2017) Developing Bettermouse Models to Study Cisplatin-Induced Kidney Injury. American Journal of Physiology Renal Physiology, 313, F835-F841. [Google Scholar] [CrossRef] [PubMed]
[19] Skrypnyk, N.I., Siskind, L.J., Faube, S. and de Caestecker, M.P. (2016) Bridging Translation for Acute Kidney Injury with Better Preclinical Modeling of Human Disease. American Journal of Physiology Renal Physiology, 310, F972-F984. [Google Scholar] [CrossRef] [PubMed]
[20] Rosen, S. and Heyman, S.N. (2001) Difficulties in Understanding Human “Acute Tubular Necrosis”: Limited Data and Flawed Animal Models. Kidney International, 60, 1220-1224. [Google Scholar] [CrossRef] [PubMed]
[21] Heyman, S.N., Rosenberger, C. and Rosen, S. (2011) Acute Kidney Injury: Lessons from Experimental Models. Contributions to Nephrology, 169, 286-296. [Google Scholar] [CrossRef] [PubMed]
[22] Kociba, R.J. and Sleight, S.D. (1971) Acute Toxicologic and Pathologic Effects of cis-Diamminedichloroplatinum (NSC-119875) in the Male Rat. Cancer Chemotherapy Reports, 55, 1-8.
[23] Fillastre, J.P. and Raguenez-Viotte, G. (1989) Cisplatin Nephrotoxicity. Toxicology Letters, 46, 163-175. [Google Scholar] [CrossRef] [PubMed]
[24] Yao, X., Panichpisal, K., Kurtzman, N. and Nugent, K. (2007) Cisplatin Ne-phrotoxicity: A Review. The American Journal of the Medical Sciences, 334, 115-124. [Google Scholar] [CrossRef] 
[25] Dasari, S. and Tchounwou, P.B. (2014) Cisplatin in Cancer Therapy: Molecular Mechanisms of Action. European Journal of Pharmacology, 740, 364-378. [Google Scholar] [CrossRef] [PubMed]
[26] dos Santos, N.A.G., Rodrigues, M.A.C., Martins, N.M. and dos Santos, A.C. (2012) Cisplatin-Induced Nephrotoxicity and Targets of Nephroprotection: An Update. Archives of Toxicology, 86, 1233-1250. [Google Scholar] [CrossRef] [PubMed]
[27] Miller, R.P., Tadagavadi, R.K., Ramesh, G. and Reeves, W.B. (2010) Mechanisms of Cisplatin Nephrotoxicity. Toxins (Basel), 2, 2490-2518. [Google Scholar] [CrossRef] [PubMed]
[28] Sanchez-Gonzalez, P.D., Lopez-Hernandez, F.J., Lopez-Novoa, J.M. and Morales, A.I. (2011) An Integrative View of the Pathophysiological Events Leading to Cisplatin Nephrotoxicity. Critical Reviews in Toxicology, 41, 803-821. [Google Scholar] [CrossRef] [PubMed]
[29] Okada, A., Fukushima, K., Fujita, M., et al. (2017) Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-Chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats. Biological & Pharmaceutical Bulletin, 40, 1948- 1955. [Google Scholar] [CrossRef] [PubMed]
[30] Siddik, Z.H., Newell, D.R., Boxall, F.E. and Harrap, K.R. (1987) The Comparative Pharmacokinetics of Carboplatin and Cisplatin in Mice and Rats. Biochemical Pharmacology, 36, 1925-1932. [Google Scholar] [CrossRef] [PubMed]
[31] Teobaldi, G., Hofer, W.A., Bikondoa, O., Pang, C.L. Cabailh, G. and Thornton, G. (2007) Modelling STM Images of TiO2(1 1 0) from First-Principles: Defects, Water Adsorption and Dissociation Products. Chemical Physics Letters, 437, 73-78. [Google Scholar] [CrossRef]